3 Year Absolute Returns
81.31% ↑
NAV (₹) on 16 Nov 2026
38.82
1 Day NAV Change
0.71%
Risk Level
Very High Risk
Rating
-
LIC MF Healthcare Fund - Direct Plan is a Equity mutual fund categorized under Sector, offered by LIC Mutual Fund Asset Management Limited. Launched on 08 Feb 2019, investors can start with a minimum ... Read more
AUM
₹ 96.54 Cr
| Sectors | Weightage |
|---|---|
| Pharmaceuticals | 59.45% |
| Hospitals & Medical Services | 32.51% |
| Treps/Reverse Repo | 3.37% |
| Chemicals - Others | 2.70% |
| Chemicals - Speciality | 1.54% |
| Net Receivables/(Payables) | 0.44% |
| Name | Weightage | Value (in Cr.) | Sector |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 8.65% | ₹ 8.36 | Pharmaceuticals |
| Divi's Laboratories Ltd. | 7.09% | ₹ 6.85 | Pharmaceuticals |
| Apollo Hospitals Enterprise Ltd. | 6.13% | ₹ 5.91 | Hospitals & Medical Services |
| Torrent Pharmaceuticals Ltd. | 5.97% | ₹ 5.77 | Pharmaceuticals |
| Neuland Laboratories Ltd. | 5.83% | ₹ 5.63 | Pharmaceuticals |
| Aurobindo Pharma Ltd. | 5.41% | ₹ 5.22 | Pharmaceuticals |
| Aster DM Quality Care Ltd. | 4.64% | ₹ 4.48 | Hospitals & Medical Services |
| Nephrocare Health Services Ltd. | 4.14% | ₹ 3.99 | Hospitals & Medical Services |
| Fortis Healthcare Ltd. | 3.87% | ₹ 3.73 | Hospitals & Medical Services |
| Metropolis Healthcare Ltd. | 3.73% | ₹ 3.60 | Hospitals & Medical Services |
| Gland Pharma Ltd. | 3.52% | ₹ 3.40 | Pharmaceuticals |
| Treps | 3.37% | ₹ 3.26 | Others |
| Zydus Lifesciences Ltd. | 3.23% | ₹ 3.11 | Pharmaceuticals |
| Cohance Lifesciences Ltd. | 3.04% | ₹ 2.93 | Pharmaceuticals |
| Piramal Pharma Ltd. | 2.97% | ₹ 2.87 | Pharmaceuticals |
| Max Healthcare Institute Ltd. | 2.85% | ₹ 2.75 | Hospitals & Medical Services |
| Mankind Pharma Ltd. | 2.84% | ₹ 2.74 | Pharmaceuticals |
| Navin Fluorine International Ltd. | 2.70% | ₹ 2.60 | Chemicals - Others |
| Dr Agarwal's Health Care Ltd. | 2.69% | ₹ 2.60 | Hospitals & Medical Services |
| Onesource Specialty Pharma Ltd. | 2.43% | ₹ 2.35 | Pharmaceuticals |
| Glenmark Pharmaceuticals Ltd. | 2.40% | ₹ 2.32 | Pharmaceuticals |
| Biocon Ltd. | 2.31% | ₹ 2.23 | Pharmaceuticals |
| IPCA Laboratories Ltd. | 2.20% | ₹ 2.12 | Pharmaceuticals |
| Yatharth Hospital&Trauma Care Serv Ltd. | 2.16% | ₹ 2.09 | Hospitals & Medical Services |
| Rainbow Children's Medicare Ltd. | 2.12% | ₹ 2.05 | Hospitals & Medical Services |
| Syngene International Ltd. | 1.56% | ₹ 1.51 | Pharmaceuticals |
| Gujarat Fluorochemicals Ltd. | 1.54% | ₹ 1.49 | Chemicals - Speciality |
| Net Receivables / (Payables) | 0.44% | ₹ 0.42 | Others |
| Global Health Ltd. | 0.18% | ₹ 0.17 | Hospitals & Medical Services |
| Annualised returns | ||||
|---|---|---|---|---|
| 9M | 1Y | 2Y | 3Y | |
| Fund returns | 25.32% | 17.78% | 10.98% | 21.94% |
| Category returns | 7.37% | 5.10% | 9.83% | 22.69% |
The objective of the Scheme is to achieve long term capital appreciation by predominantly investing in equity and equity related instruments of companies engaged in Healthcare and Allied sectors.
|
Scheme Name
|
NAV
|
Returns
1Y
3Y
5Y
|
AUM (Cr)
|
Expense Ratio
|
Risk Meter
|
||
|---|---|---|---|---|---|---|---|
|
Nippon India Taiwan Equity fund - Direct Plan
Sector
Direct
|
₹26.37 | 50.25% | 184.01% | 0.00% | ₹963 | 1.06% |
Very High
|
|
Nippon India Taiwan Equity fund - Direct Plan
Sector
Direct
|
₹26.37 | 50.25% | 184.01% | 0.00% | ₹963 | 1.06% |
Very High
|
|
Nippon India Taiwan Equity fund - Direct Plan
Sector
Direct
|
₹26.37 | 50.25% | 184.01% | 0.00% | ₹963 | 1.06% |
Very High
|
|
Nippon India Taiwan Equity Fund
Sector
Regular
|
₹24.56 | 48.26% | 172.60% | 0.00% | ₹963 | 2.34% |
Very High
|
|
Nippon India Taiwan Equity Fund
Sector
Regular
|
₹24.56 | 48.26% | 172.60% | 0.00% | ₹963 | 2.34% |
Very High
|
|
Nippon India Taiwan Equity Fund
Sector
Regular
|
₹24.56 | 48.26% | 172.60% | 0.00% | ₹963 | 2.34% |
Very High
|
|
HDFC Defence Fund - Direct Plan
Sector
Direct
|
₹30.12 | 18.09% | 129.70% | 0.00% | ₹11,131 | 0.89% |
Very High
|
|
HDFC Defence Fund - Direct Plan
Sector
Direct
|
₹30.12 | 18.09% | 129.70% | 0.00% | ₹11,131 | 0.89% |
Very High
|
|
HDFC Defence Fund - Direct Plan
Sector
Direct
|
₹30.12 | 18.09% | 129.70% | 0.00% | ₹11,131 | 0.89% |
Very High
|
|
HDFC Pharma and Healthcare Fund - Direct Plan
Sector
Direct
|
₹23.46 | 30.32% | 124.36% | 0.00% | ₹3,666 | 1.03% |
Very High
|
|
Scheme Name
|
NAV
|
Returns
1Y
3Y
5Y
|
AUM (Cr)
|
Expense Ratio
|
Risk Meter
|
||
|---|---|---|---|---|---|---|---|
|
LIC MF Gold ETF
ETF
Regular
|
₹120.48 | 6.43% | 117.26% | 163.19% | ₹1,378 | 0.45% |
High
|
|
LIC MF Gold ETF FOF - Direct Plan
Fund of Funds
Direct
|
₹36.29 | 5.45% | 113.38% | 159.77% | ₹797 | 0.35% |
High
|
|
LIC MF Gold ETF FOF
Fund of Funds
Regular
|
₹34.28 | 5.16% | 111.03% | 154.82% | ₹797 | 0.61% |
High
|
|
LIC MF Healthcare Fund - Direct Plan
Sector
Direct
|
₹38.84 | 17.78% | 81.36% | 96.44% | ₹97 | 1.37% |
Very High
|
|
LIC MF Healthcare Fund - Direct Plan
Sector
Direct
|
₹38.82 | 17.78% | 81.31% | 96.37% | ₹97 | 1.37% |
Very High
|
|
LIC MF Infrastructure Fund - Direct Plan
Sector
Direct
|
₹62.84 | 9.27% | 79.66% | 151.39% | ₹1,100 | 1.33% |
Very High
|
|
LIC MF Infrastructure Fund - Direct Plan
Sector
Direct
|
₹61.70 | 9.27% | 79.57% | 150.38% | ₹1,100 | 1.33% |
Very High
|
|
LIC MF Infrastructure Fund - Direct Plan
Sector
Direct
|
₹61.70 | 9.27% | 79.57% | 150.38% | ₹1,100 | 1.33% |
Very High
|
|
LIC MF Healthcare Fund
Sector
Regular
|
₹34.97 | 16.22% | 74.61% | 84.62% | ₹97 | 2.67% |
Very High
|
|
LIC MF Healthcare Fund
Sector
Regular
|
₹34.97 | 16.22% | 74.61% | 84.62% | ₹97 | 2.67% |
Very High
|
What is the current NAV of LIC MF Healthcare Fund - Direct Plan IDCW-Reinvestment?
What is the fund size (AUM) of LIC MF Healthcare Fund - Direct Plan IDCW-Reinvestment?
What are the historical returns of LIC MF Healthcare Fund - Direct Plan IDCW-Reinvestment?
What is the risk level of LIC MF Healthcare Fund - Direct Plan IDCW-Reinvestment?
What is the minimum investment amount for LIC MF Healthcare Fund - Direct Plan IDCW-Reinvestment?
Disclaimer: This is 3rd Party content/feed, viewers are requested to use their discretion and conduct proper diligence before investing, GoodReturns does not take any liability on the genuineness and correctness of the information in this article